Avance Biosciences is excited to exhibit at the ASGCT 2025 conference in New Orleans, LA, from May 13–17, 2025. Join us to explore our expert bioanalytical solutions for gene and cell therapy development. Visit booth #750 to learn how we can support your therapeutic advancements...
Avance Biosciences™ is joining the 2025 AAPS National Biotechnology Conference to showcase our expertise in biological assay development, validation, and sample testing. Visit our booth to learn more about our innovative solutions and explore potential collaborations in drug development...
Avance Biosciences is excited to participate in the World Vaccine Congress 2025, showcasing our advanced solutions in vaccine development, bioanalytics, and regulatory compliance. Join us to explore collaboration opportunities and learn how our services can support your vaccine research and clinical trials...
Avance Biosciences offers CLIA-compliant testing services to ensure accurate, reliable data throughout drug development. From biomarker validation to regulatory support, our expertise helps biopharmaceutical companies advance clinical trials and bring innovative biologic treatments to market with confidence...
Avance Biosciences is excited to join WRIB 2025 in New Orleans, showcasing our expertise in bioanalytical testing for biologics and biosimilars. Visit us at Booth #78 to explore our advanced solutions, including LBA, Flow Cytometry, qPCR, and LC-MS/MS. [...]
Beam Therapeutics announces groundbreaking results from its Phase 1/2 trial of BEAM-302, demonstrating the first-ever clinical genetic correction for Alpha-1 Antitrypsin Deficiency (AATD), offering hope for a potential one-time cure for this genetic disorder...
TIGR (Tandem Interspaced Guide RNA) systems use RNA guides to target specific DNA sites, offering a compact and modular alternative to CRISPR. Scientists at MIT and the Broad Institute discovered over 20,000 TIGR-associated proteins, some capable of precise DNA cutting, potentially expanding genome...
Avance Biosciences™ announces CLIA registration, expanding its high-complexity laboratory testing capabilities for clinical trials, regulatory submissions, and companion diagnostics. This milestone strengthens its commitment to high-quality, regulatory-compliant testing solutions that accelerate drug...
A groundbreaking gene therapy using rAAV8.hRKp.AIPL1 has restored vision in 11 children with AIPL1-related retinal dystrophy (LCA4), who were blind at birth. Published in The Lancet, the study shows significant improvements in visual acuity and retinal preservation, supporting expedited approval...
Avance Biosciences is excited to announce its participation in the upcoming SITC Conference, taking place from November 6-10, 2024, in Houston TX. This premier event is focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. [...]
